US Patent Issued to Novocure on May 6 for "Treating tumors using TTFields combined with a PARP inhibitor" (Texas Inventors)

ALEXANDRIA, Va., June 10 -- United States Patent no. 12,290,652, issued on May 6, was assigned to Novocure GmbH (Baar, Switzerland).

"Treating tumors using TTFields combined with a PARP inhibitor" was invented by Michael Story (Austin, Texas), Debabrata Saha (Carrollton, Texas) and Narasimha Kumar Karanam (Dallas).

According to the abstract* released by the U.S. Patent & Trademark Office: "Tumor-Treating Fields elicit a conditional vulnerability to PARP inhibitors (e.g., Olaparib) in certain cancer cells such as non-small cell lung cancer (NSCLC) cell lines. This conditional vulnerability is exploited in a method of killing cancer cells that comprises delivering a PARP inhibitor to the cancer cells and applying an alternating 80-300 kHz e...